Vroman, H. et al (2020). T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma. 

Belderbos, R.A. et al (2020). Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma. Front Oncol. 2020 Jun 3;10:777.

Belderbos, R.A. et al (2019). A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial. Transl Lung Cancer Res. 2019 Jun;8(3):280-285

Belderbos, R.A. et al (2019). Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment. Mol Ther Oncolytics. 2019 Mar 27;13:67-81

De Boer, N.L. et al (2019). Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial. BMJ Open. 2019 May 14;9(5):e026779

Van Gulijk, M et al (2018). Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy. Front Immunol. Dec 5;9:2759. eCollection. Review.

Huber, A. et al (2018). Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?
Front Immunol. Dec 3;9:2804. eCollection. Review.

Noordam, L. et al (2018). Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy. Oncoimmunology. Jul 30;7(12): eCollection 2018.

de Goeje, P.L. et al (2018). Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS. Front Immunol. Sep 7;9:2034.

Aerts, J. et al (2018). Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human. Clin Cancer Res 24(4): 1–11.

Dammeijer, F. et al (2017). Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. Cytokine Growth Factor Rev. Aug;36:5-15. Review.

Dammeijer, F. et al (2017). Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy. Cancer Immunol Res. Jul;5(7):535-546.

Dammeijer, F. et al (2016). Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. J Clin Oncol. Sep 10;34(26):3204-12. Epub 2016 Jul 18. Review.

Cornelissen, R. et al. (2016). Consolidation Immunotherapy in Mesothelioma. Am J Respir Crit Care Med 193(9): 1023–1031.

Hegmans, J. and J. Aerts (2013). Immunological profiling as a means to invigorate personalized cancer therapy. Oncoimmunology, 2(8): e25236.

Aerts, J. and J. Hegmans (2013). Tumour-specific cytotoxic T-cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res 73: 2381-8.

Cornelissen, R. et al. (2012). New roads open up for implementing immunotherapy in mesothelioma. Clin Dev Immunol: 927240.

Cornelissen, R. et al. (2012). Dendritic cell-based immunotherapy in mesothelioma. Immunotherapy 4(10): 1011- 1022.

Hegmans, J. et al. (2010). Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med 181(12): 1383-1390.

Veltman, J. et al. (2010). Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity. J Biomed Biotechnol: 798467.

Hegmans, J. et al. (2006). Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 27(6): 1086-1095.

Hegmans, J. et al. (2005). Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am J Respir Crit Care Med 171(10): 1168-1177.